These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36249041)

  • 1. The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy.
    Wang Y; Song Z; Geng Y; Gao L; Xu L; Tang G; Ni X; Chen L; Chen J; Wang T; Fu W; Feng D; Yu X; Wang L; Yang J
    Front Oncol; 2022; 12():987965. PubMed ID: 36249041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
    Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
    Transplant Cell Ther; 2024 Apr; 30(4):404-414. PubMed ID: 38281589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy.
    Gong WJ; Qiu Y; Li MH; Chen LY; Li YY; Yu JQ; Kang LQ; Sun AN; Wu DP; Yu L; Xue SL
    Front Immunol; 2022; 13():922212. PubMed ID: 36105799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
    Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
    Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
    Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
    BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
    Gu J; Liu S; Cui W; Dai H; Cui Q; Yin J; Li Z; Kang L; Qiu H; Han Y; Miao M; Chen S; Xue S; Wang Y; Jin Z; Zhu X; Yu L; Wu D; Tang X
    Front Immunol; 2022; 13():858590. PubMed ID: 35371098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
    He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
    Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
    Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
    Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
    J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse.
    Huang L; Zhang M; Wei G; Zhao H; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):151-159. PubMed ID: 36161297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
    Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
    Front Immunol; 2022; 13():879030. PubMed ID: 35558072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
    Huang C; Wu L; Liu R; Li W; Li Z; Li J; Liu L; Shan B
    Ann Transl Med; 2020 Sep; 8(17):1048. PubMed ID: 33145267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.